Current algorithms for the use of HCV virological tools in the treatment of chronic hepatitis C, according to the HCV genotype: genotype 1 (A), genotypes 2 and 3 (B), and genotypes 4, 5 and 6 (C) The approved dose of pegylated IFN alfa-2a is 180 g per week, independent of body weight, whereas that of pegylated IFN alfa-2b is weight-adjusted at 1.5 g/kg per week, identical for all HCV genotypes
Patient adherence to dosing recommendations and lifestyle modifications can substantially impact how quickly tolerance develops and symptoms resolve
What is the retatrutide mechanism of action
Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE et al (2019) Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: a post hoc analysis of the LEADER and SUSTAIN 6 clinical trials